TOP 3 REASONS PHARMA SHOULD USE VELOCITY FOR GENAI
By Ashley Larrimore - Head of Marketing
As the head of marketing, I am constantly thinking about how to highlight and convey the benefits of VELOCITY, our AI Operations Platform for Pharma. Generative AI (GenAI) is a hot topic and so I went to the CEO, President and Executive Director of Customer Engagement individually and asked, “What is your top reason why Pharma should use VELOCITY for GenAI?” They all gave very different answers, and I liked what I heard. The following post summarizes the answers.
RAPID AND COST EFFECT PILOTING TO PRODUCTION
Jennifer Jones - Executive Director of Customer Engagement
Capitalizing on the capabilities of GenAI is new, and not just for Pharma. Many good use cases are floating around but there are very few tangible implementations. This is to be expected as GenAI, even with its amazing abilities, is not an out-of-the-box solution. There will be a lot of kicking the tires over the next year as use cases are tried out and best practices are established.
Our customers need a solution that allows for many pilots to be executed in a cost-effective and timely manner. They also need to be able to keep tabs on what projects are going on and make sure the learnings from each effort are carried forward to the next one. These pilots have to be conducted in a fully secure and scalable manner in order to seamlessly transition the high-value use cases to production.
VELOCITY provides the means to accomplish these goals. From the GenAI accelerators that can be custom-tailored in a month or less to the architecture of the platform that provides security, manageability, and scalability, VELOCITY enables rapid GenAI piloting and production. Many point solutions address an individual capability, but none tie it all together like VELOCITY does to allow our customers to quickly, securely, and effectively use GenAI to answer business questions.
PROMPTS, PROMPTS, PROMPTS
Rich Sokolosky - CEO
SENTIER started as an advanced analytics company delivering high-value ML-driven insights to drive performance across a host of business functions. We have always focused solely on Pharma and along the way, developed deep expertise in the industry, the data needed to run the analytics and of course the analytics themselves.
When GenAI came along, it literally dropped in our lap. GenAI has the potential to dramatically change the cost structure and utility of AI for our customers but it does not come easily (contrary to what many vendors say). The foundation LLMs don’t know anything about pharma-specific data and analytic domains. They need to be taught or prompted with context to come to the right conclusions. Teaching (training) a private LLM is a cost-prohibitive endeavor for all but the biggest budgets so prompting general use LLMs is the go-to solution for the foreseeable future.
We do prompts extremely well and bake those capabilities into VELOCITY’s accelerators. Given the origin of the company, we already have the questions, data definitions, business examples, and model engineering expertise to direct the LLM to the right answer (no “hallucinations”). Our accelerators package up this expertise and can be leveraged to deliver tangible GenAI results. Targeted GenAI applications can be effective but at this early stage, when everything is on the table, having an advanced starting point from which to quickly explore multiple angles for our customers puts us ahead of the game. VELOCITY’s ability to wrap operations around GenAI is icing on the cake.
RESPONSIBLE AI
Chael Christopher - President
As President, I am tasked with the operations of the company. One of the things that I go to bed and wake up thinking about is security. Is there anything further we can do to protect our customers’ data and IP? GenAI poses some new challenges but at the end of the day, it is another form of AI that requires all the confidentiality and protection afforded to those that came before. In a broader context, security is one component of our Responsible AI (RAI) principles which also include bias-free predictions, transparency in methodology, and continuous enhancement. These are not just words we put on a presentation but something that everyone in the company is aware of and strives for when delivering and enhancing VELOCITY.
A lot of people think GenAI is the public version of ChatGPT. For our customers, it is decidedly not. Foundation models are accessed through the major players (AWS, Azure), complex data structures need to be provisioned, prompts containing sensitive information need to be passed to those LLMs in a secure way, results need to be checked for validity, activity needs to be tracked…and the list goes on. Delivering GenAI results in a business context is a complex endeavor.
So, to answer the question, Pharma customers should use VELOCITY for GenAI because we have thought about RAI and end-to-end AI operations, worked with experts to implement them in an industry leading AIOps platform, and we continue to improve and stay ahead of the competition.
FINAL THOUGHTS
Ashley Larrimore - Head of Marketing
So, what do you think? Are you struggling to gain traction with your data science efforts? Are data science projects dying on the vine at your company because someone leaves or are other questions consuming the mindshare and time of your data scientists? Is RAI (responsible AI) part of your company’s culture?
Head over to our LinkedIn post here and share your thoughts.
--
Since 2017, SENTIER has been disrupting the utility and ROI of AI for pharmaceutical and biotech companies. Through VELOCITY, the first AI Operations Platform purpose built for life sciences, our customers are realizing a 90% reduction in the data science resources required to deliver answers from advanced analytics and a 25% increase in business effectiveness. By automating AI, VELOCITY democratizes insights, drives innovation, and lowers costs.
